NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
PROVENTIL (albuterol sulfate) by Merck & Co. is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 1987.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROVENTIL (albuterol sulfate) is an oral extended-release beta-2 adrenergic agonist bronchodilator approved in 1987 for asthma and COPD. It works by stimulating adenyl cyclase to increase cyclic AMP, causing bronchial smooth muscle relaxation with onset of improvement within 5 minutes and peak effect at approximately 1 hour.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals transition planning and potential team restructuring toward LOE management.
Mechanism of Action
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on PROVENTIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.